La Jolla Pharmaceutical Co
F:LJPP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
LJPP's latest stock split occurred on Jan 14, 2014
The company executed a 1-for-50 stock split, meaning that for every 50 shares held, investors received 1 new share.
The adjusted shares began trading on Jan 14, 2014. This was LJPP's 3rd stock split, following the previous one in Feb 17, 2012.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 22, 2026
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
1-for-100
/100
|
0.002 0.2 AUD | 0.17 0.17 AUD |
|
Apr 22, 2026
|
|
Architects Studio Japan Inc
TSE:6085
|
10-for-1
x10
|
3800 380 JPY | 430 430 JPY |
|
Apr 22, 2026
|
|
Freewon China Co Ltd
SSE:688678
|
1-for-1
x1
|
30.5 21.6857 CNY | 23.64 23.64 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
|
Apr 21, 2026
|
|
Canon Electronics Inc
OTC:CAOEF
|
1-for-6235122
/6235122
|
16.96 16.96 USD | N/A |
CHM
6085
688678
CAOEF
La Jolla Pharmaceutical Co
Glance View
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
